{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.64","upperLimit":"46.95","value":"18.5"},{"groupId":"OG001","lowerLimit":"5.19","upperLimit":"54.34","value":"18.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg","id":"OG000","title":"Fulvestrant + Anastrozole"},{"description":"Anastrozole 1 mg","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009","title":"Duration of Clinical Benefit (DoCB)","type":"SECONDARY","unitOfMeasure":"months"}